Literature DB >> 20227473

T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes.

Hiroyuki Koide1, Tomohiro Asai, Kentaro Hatanaka, Shuji Akai, Takayuki Ishii, Eriya Kenjo, Tatsuhiro Ishida, Hiroshi Kiwada, Hideo Tsukada, Naoto Oku.   

Abstract

Repeated injection of polyethyleneglycol-modified (PEGylated) liposomes causes a rapid clearance of them from the bloodstream, this phenomenon is called accelerated blood clearance (ABC). In the present study, we focused on the immune system responsible for the ABC phenomenon. PEGylated liposomes were preadministered to BALB/c mice and [(3)H]-labeled ones were then administered to them 3 days after the preadministration. Consistent with our previous results, the preadministration with PEGylated liposomes triggered the rapid clearance of [(3)H]-labeled PEGylated liposomes from the bloodstream, but that with PEGylated liposomes encapsulating doxorubicin (Dox) did not. In addition, we found that the ABC phenomenon was observed when a mixture of free Dox and PEGylated liposomes was preadministered. These data indicate that immune cells responsible for the ABC phenomenon might be selectively damaged by the Dox encapsulated in PEGylated liposomes. The ABC phenomenon was also observed in BALB/c nu/nu mice, but not in BALB/c SCID mice. The amount of anti-PEG IgM antibody induced by the stimulation with the PEGylated liposomes was significantly increased in the BALB/c nu/nu mice, but not in the BALB/c SCID ones. These data indicate that a T cell-independent B cell response would play a significant role in the ABC phenomenon. Furthermore, the present study suggests that PEGylated liposomes might be recognized by B cells as a thymus-independent type 2 (TI-2) antigen. The present study provides important information for the future development of liposomal medicines. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20227473     DOI: 10.1016/j.ijpharm.2010.03.022

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  32 in total

1.  Factors influencing in vivo disposition of polymeric micelles on multiple administrations.

Authors:  Eri Hara; Motoki Ueda; Akira Makino; Isao Hara; Eiichi Ozeki; Shunsaku Kimura
Journal:  ACS Med Chem Lett       Date:  2014-06-18       Impact factor: 4.345

2.  Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers.

Authors:  Angelo Moreno; George A Pitoc; Nancy J Ganson; Juliana M Layzer; Michael S Hershfield; Alice F Tarantal; Bruce A Sullenger
Journal:  Cell Chem Biol       Date:  2019-02-28       Impact factor: 8.116

Review 3.  Anti-PEG immunity: emergence, characteristics, and unaddressed questions.

Authors:  Qi Yang; Samuel K Lai
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2015-02-23

4.  Riboflavin-containing telodendrimer nanocarriers for efficient doxorubicin delivery: High loading capacity, increased stability, and improved anticancer efficacy.

Authors:  Dandan Guo; Changying Shi; Xu Wang; Lili Wang; Shengle Zhang; Juntao Luo
Journal:  Biomaterials       Date:  2017-06-30       Impact factor: 12.479

5.  PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice.

Authors:  Aaron Peng; Matthew P Kosloski; Genki Nakamura; Hong Ding; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2011-12-16       Impact factor: 4.009

Review 6.  Designer lipids for drug delivery: from heads to tails.

Authors:  Aditya G Kohli; Paul H Kierstead; Vincent J Venditto; Colin L Walsh; Francis C Szoka
Journal:  J Control Release       Date:  2014-05-06       Impact factor: 9.776

7.  Questioning the Use of PEGylation for Drug Delivery.

Authors:  Johan J F Verhoef; Thomas J Anchordoquy
Journal:  Drug Deliv Transl Res       Date:  2013-12       Impact factor: 4.617

Review 8.  Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future.

Authors:  Anna N Ilinskaya; Marina A Dobrovolskaia
Journal:  Toxicol Appl Pharmacol       Date:  2016-01-07       Impact factor: 4.219

Review 9.  Polymer-drug conjugates: origins, progress to date and future directions.

Authors:  Jindřich Kopeček
Journal:  Adv Drug Deliv Rev       Date:  2012-11-02       Impact factor: 15.470

Review 10.  Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology.

Authors:  Lígia Catarina Gomes-da-Silva; Sérgio Simões; João Nuno Moreira
Journal:  Cell Mol Life Sci       Date:  2013-11-13       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.